Moleculin Biotech has reported a preliminary 37% composite complete remission rate among 62 evaluable patients in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia. The July 31 update also showed a 24% complete remission rate across the blinded study population. Among 30 evaluable
MIRACLE reports a 37% blinded composite remission rate in relapsed AML, including patients who previously failed venetoclax treatment.
Find out how Annamycin could bridge chemotherapy and immunotherapy in pancreatic cancer and what AACR 2026 data signals for future trials.
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.
Independent reviewers found no cardiotoxicity for Moleculin’s annamycin in 90 subjects. See how this safety milestone may reshape its oncology development path.